Compass Pathways rises after FDA fast-tracks psychedelic drug research

COMPASS Pathways

24/04/2026 14:38

** Shares of Compass Pathways CMPS.O rise 5.52% to $9.66

** The U.S. FDA said on Friday it is taking steps to speed up the development of new treatments for serious mental illness, following an executive order signed by President Donald Trump

** The executive order, signed on Saturday, intended to speed up access to medical research and treatment based on psychedelic drugs

** FDA said it would issue special priority vouchers to three companies developing psychedelic treatments

** Other psychedelic drug developers Enveric Biosciences ENVB.O up 3.36%, U.S.-listed shares of Cybin HELP.O up 6.26%

 (Reporting by Sriparna Roy in Bengaluru)

 ((Sriparna.Roy@thomsonreuters.com;))